1. Scrip
  2. >>New Products

Gamida Cell Bounces Back With Omisirge US Approval

For Use In Hematological Malignancies

 
• By Ayisha Sharma

The Israeli firm Gamida Cell’s lead candidate has obtained a US approval as a new donor source for allogeneic stem cell transplant with the chips in place for independent commercialization despite its recent financial troubles.  

Stem Cells, 3D rendering. - Illustration
Omisirge Makes Use Of Gamida's NAM Technology • Source: Alamy

Gamida Cell Ltd.’s allogeneic cell therapy Omisirge will provide a new option for patients with hematological malignancies waiting for stem cell transplant after the US Food and Drug Administration granted it an approval, marking a positive turn in the company’s story.

Omisirge (omidubicel-onlv) uses Gamida’s proprietary nicotinamide (NAM) technology to enhance and expand the number of progenitor cells and is priced at $338,000 per treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.